Growth Metrics

Eli Lilly (LLY) Long-Term Deferred Tax (2017 - 2026)

Eli Lilly filings provide 10 years of Long-Term Deferred Tax readings, the most recent being $11.4 billion for Q1 2026.

  • On a quarterly basis, Long-Term Deferred Tax rose 32.39% to $11.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $11.4 billion, a 32.39% increase, with the full-year FY2025 number at $10.0 billion, up 24.47% from a year prior.
  • Long-Term Deferred Tax hit $11.4 billion in Q1 2026 for Eli Lilly, up from $10.0 billion in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $11.4 billion in Q1 2026 to a low of $2.4 billion in Q2 2022.
  • Median Long-Term Deferred Tax over the past 5 years was $5.6 billion (2024), compared with a mean of $6.1 billion.
  • Biggest five-year swings in Long-Term Deferred Tax: decreased 11.33% in 2022 and later surged 96.12% in 2023.
  • Eli Lilly's Long-Term Deferred Tax stood at $2.8 billion in 2022, then skyrocketed by 96.12% to $5.5 billion in 2023, then surged by 46.08% to $8.0 billion in 2024, then increased by 24.47% to $10.0 billion in 2025, then grew by 13.97% to $11.4 billion in 2026.
  • The last three reported values for Long-Term Deferred Tax were $11.4 billion (Q1 2026), $10.0 billion (Q4 2025), and $9.0 billion (Q3 2025) per Business Quant data.